Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines

The primary objective of this statement is to review the evidence on the efficacy, effectiveness, immunogenicity, safety, and cost-effectiveness of PNEU-C-15 and PNEU-C-20 vaccines and provide recommendations for their use in consideration of the disease burden in Canada among adults for whom pneumococcal vaccination is currently recommended: immunocompetent adults aged 65 and older immunocompetent adults at higher risk of pneumococcal disease (PD), immunocompetent adults residing in long term care facilities (LTCF), immunocompromised adults, including hematopoietic stem cell transplant recipients